戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed, and 168 (83 on afatinib + cetuximab and 85 on afatinib) were eligible.
2 logical, head and neck, lung, lymphoma, or melanoma cancers were eligible.
3 d lumacaftor-ivacaftor from January 1 to December 31, 2016, were eligible.
4 s undergoing FMT in clinical practices across North America were eligible.
5  age) in the practice of a single pediatric ophthalmologist were eligible.
6 tising at each club, 426 men registered interest; 306 (72%) were eligible.
7 on of NT-proBNP (N-terminal pro-B-type natriuretic peptide) were eligible.
8 insertion into the most suspicious axillary lymph node (LN) were eligible.
9 rea Health Screening Examination within 1 year of pregnancy were eligible.
10 July 2018, consecutive patients from the SwissTAVI Registry were eligible.
11 a, and were on stable doses of anti-parkinsonian medication were eligible.
12 ive participants not on medication assisted treatment (MAT) were eligible.
13                      Nine hundred and ninety-three patients were eligible (56% male; 44% female; median age 62 years), 35
14 critically ill adults who had a tracheostomy tube; patients were eligible after weaning from mechanical ventilation.
15 g for HIV testing or care, including those newly diagnosed, were eligible and ready for same-day initiation under the SLA
16 with serotype-Ia or III at birth, and their healthy infants were eligible as matched controls.
17                                                    Patients were eligible at first relapse or first designation of refrac
18 ty-one children were estimated to suffer FA among those who were eligible but refused DBPCFC.
19 e-to-face interviews and/or skin prick testing, 238 (10.4%) were eligible for a DBPCFC.
20 f 44 676 reports were identified, and 243 OPSs and 153 RCTs were eligible for analysis after exclusion based on pre-decid
21              Four thousand two hundred seventy-six patients were eligible for analysis of baseline characteristics and 32
22                          Of 180 329 TB cases, 126 431 (70%) were eligible for analysis, with 359 (0.28%) of eligible case
23 ged 15 years or older who initiated ART at a programme site were eligible for analysis.
24 atio >=0.9 as documented by computer tomography angiography were eligible for enrollment.
25                        Of 1184 articles screened, 7 studies were eligible for final inclusion (n = 941).
26            In the clinical study, 24 in vivo-in vitro pairs were eligible for further analysis, with 4 having been reject
27                         Fourteen randomized clinical trials were eligible for inclusion (96 158 participants), of which 1
28                                                      Trials were eligible for inclusion if published between 2008 and 201
29                                                     Studies were eligible for inclusion if they assessed the potential di
30  in Athens, Greece, between December 2014 and December 2017 were eligible for inclusion.
31 tered between 2008-2015 without prior comorbidity diagnoses were eligible for inclusion.
32 5000 publications, identifying 103 data papers, of which 81 were eligible for inclusion.
33 re identified, and 68 papers reporting on 56 unique studies were eligible for inclusion.
34 earch strategy identified 131 relevant studies, of which 19 were eligible for inclusion: 12 examining cognitive behaviour
35                                     A total of 293 patients were eligible for intention-to-treat analysis: 157 in the con
36 %, 104 livebirths and 43 spontaneous or elective abortions) were eligible for post-pregnancy viral load trajectory analys
37                                    Adults (aged >=18 years) were eligible for randomization on day 5 (+/-1 d) of microbio
38 th confirmed infertility or the need for semen donation who were eligible for standard bolus intra-uterine insemination (
39 ndations among adults without a history of ASCVD or T2D who were eligible for statin treatment initiation.
40 Previously untreated patients with classic Hodgkin lymphoma were eligible for study enrolment if they were 60 years or ol
41 ore treatment with (223)Ra and at treatment discontinuation were eligible for the study.
42 he American Association for the Study of Liver Diseases who were eligible for treatment with TACE were enrolled.
43                                                These groups were eligible for US government benefits to help them resettl
44                                                     Records were eligible if they included any instrument developed, test
45                                                    Patients were eligible if they were aged 50 years or older, had been t
46                                                 Instruments were eligible if they were originally developed to measure th
47     A total of 81.5% of medical/healthcare participants who were eligible registered, and 71.5% of all eligible participa
48                                                 All studies were eligible that investigated the impact of fluid overload
49                                                Of these, 32 were eligible to be included in the study.
50 east 12 years with grades II to IV steroid-refractory aGVHD were eligible to receive ruxolitinib orally, starting at 5 mg